APP
CBAY

Avantax Planning Partners’s Cymabay Therapeutics CBAY Stock Holding History

Avantax Planning Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-219
Closed -$2K – 1269
2018
Q3 		$2K Buy
+219
New +$2.72K ﹤0.01% 1377

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Avantax Planning Partners's CBAY Position: Q4 2018 in Review

Avantax Planning Partners sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 219 shares — an estimated $2K sold.

Avantax Planning Partners first reported a position in CBAY in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • Avantax Planning Partners reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 219 Cymabay Therapeutics shares in Q4 2018, an estimated $2K.
  • Avantax Planning Partners first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Cymabay Therapeutics position peaked at $2K in Q3 2018.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.